An Open Study to Investigate the Safety and Efficacy of Replenine®-VF in Severe Haemophilia B Patients
Launched by BIO PRODUCTS LABORATORY · Sep 3, 2014
Trial Information
Current as of July 22, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Previously treated patients
- • At least 12 years of age
- • Severe Haemophilia B and without inhibitor to factor IX
- Exclusion Criteria:
- • -
About Bio Products Laboratory
Bio Products Laboratory (BPL) is a leading global biopharmaceutical company specializing in the development, manufacture, and distribution of immunoglobulin therapies and other bioproducts derived from human plasma. With a commitment to innovation and quality, BPL focuses on addressing unmet medical needs through advanced research and clinical trials. The company adheres to stringent regulatory standards, ensuring the safety and efficacy of its products while striving to improve patient outcomes across a range of conditions. Leveraging a robust pipeline and state-of-the-art facilities, BPL is dedicated to enhancing healthcare solutions worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
London, , United Kingdom
Lodz, , Poland
Lublin, , Poland
Cambridge, , United Kingdom
Cardiff, , United Kingdom
Manchester, , United Kingdom
Norwich, , United Kingdom
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials